International Biotechnology Trust (LSE:IBT) Other Current Receivables: £0.00 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:IBT International Biotechnology Trust PLC LSE:IBT
36 GF Score
Price £10.85
! 4 Warning Signs
View Full Analysis

What is International Biotechnology Trust Other Current Receivables?

International Biotechnology Trust LSE:IBT +0.46% 36 Other Current Receivables is £0.00 Mil as of Feb. 2026. GuruFocus rates LSE:IBT with a GF Score™ of 36/100. The stock has 4 warning signs investors should review.

International Biotechnology Trust's Other Current Receivables for the quarter that ended in Feb. 2026 was £0.00 Mil.

International Biotechnology Trust Other Current Receivables Related Terms

International Biotechnology Trust Other Current Receivables Historical Data

* Premium members only.

The historical data trend for International Biotechnology Trust's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Biotechnology Trust Other Current Receivables Chart

International Biotechnology Trust Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

International Biotechnology Trust Semi-Annual Data
Aug16 Feb17 Aug17 Feb18 Aug18 Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Aug22 Feb23 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:IBT
36GF Score
International Biotechnology Trust PLC LSE:IBT
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

International Biotechnology Trust Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of £0.00 Mil mean?
International Biotechnology Trust (LSE:IBT) has a Other Current Receivables of £0.00 Mil as of Feb. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on International Biotechnology Trust and its competitors.
Is International Biotechnology Trust's Other Current Receivables too high?
International Biotechnology Trust's current Other Current Receivables is £0.00 Mil. Overall, International Biotechnology Trust has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does International Biotechnology Trust's Other Current Receivables compare to VRTX and REGN?
International Biotechnology Trust's Other Current Receivables of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on International Biotechnology Trust and its competitors. International Biotechnology Trust's current Other Current Receivables is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Biotechnology Trust stock overvalued right now?
International Biotechnology Trust (LSE:IBT) has a current Other Current Receivables of £0.00 Mil. The current Other Current Receivables is £0.00 Mil. International Biotechnology Trust's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For International Biotechnology Trust (LSE:IBT), the current Other Current Receivables is £0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

International Biotechnology Trust Business Description

Address 1 London Wall Place, London, GBR, EC2Y 5AU
International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.
36GF Score

Get the complete analysis for LSE:IBT

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£10.85
Price